Nothing Special   »   [go: up one dir, main page]

AR033520A1 - (5r)-(metilamino) -5,6-dihidro-4h-imidazo[4,5,1-ij] quinolin-2(1h)-tiona - Google Patents

(5r)-(metilamino) -5,6-dihidro-4h-imidazo[4,5,1-ij] quinolin-2(1h)-tiona

Info

Publication number
AR033520A1
AR033520A1 ARP010101768A ARP010101768A AR033520A1 AR 033520 A1 AR033520 A1 AR 033520A1 AR P010101768 A ARP010101768 A AR P010101768A AR P010101768 A ARP010101768 A AR P010101768A AR 033520 A1 AR033520 A1 AR 033520A1
Authority
AR
Argentina
Prior art keywords
quinolin
imidazo
dihidro
tiona
methylamine
Prior art date
Application number
ARP010101768A
Other languages
English (en)
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of AR033520A1 publication Critical patent/AR033520A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

(5R)-5-(metilamino)-5,6-dihidro-4H-imidazo[4, 5,1-ij] quinolin-2(1H)-tiona, formula 1 y sales farmacéuticamente aceptables del mismo. El compuesto es de utilidad en el campo farmacéutico para el tratamiento de la enfermedad de Parkinson y diversas disfunciones sexuales.
ARP010101768A 2000-04-27 2001-04-16 (5r)-(metilamino) -5,6-dihidro-4h-imidazo[4,5,1-ij] quinolin-2(1h)-tiona AR033520A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19995400P 2000-04-27 2000-04-27
US23410100P 2000-09-21 2000-09-21

Publications (1)

Publication Number Publication Date
AR033520A1 true AR033520A1 (es) 2003-12-26

Family

ID=26895318

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010101768A AR033520A1 (es) 2000-04-27 2001-04-16 (5r)-(metilamino) -5,6-dihidro-4h-imidazo[4,5,1-ij] quinolin-2(1h)-tiona

Country Status (10)

Country Link
US (3) US20020137763A1 (es)
JP (1) JP2003531907A (es)
KR (1) KR20020093090A (es)
CN (1) CN1420886A (es)
AR (1) AR033520A1 (es)
AU (1) AU2001255225A1 (es)
BR (1) BR0110323A (es)
CA (1) CA2404936A1 (es)
PE (1) PE20011181A1 (es)
WO (1) WO2001083483A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR031152A1 (es) * 2000-10-31 2003-09-10 Upjohn Co Tratamientos nuevos para el sindrome de piernas inquietas
AU2003277298A1 (en) * 2002-10-04 2004-05-04 Pharmacia Corporation Pharmaceutical compositions for treatment of parkinson's disease
WO2007006677A1 (en) 2005-07-13 2007-01-18 F. Hoffmann-La Roche Ag Benzimidazole derivatives as 5-ht6,5-ht24
CN111349094B (zh) * 2020-04-23 2021-02-02 杭州师范大学 一种6H-咪唑[4,5,1-ij]并喹诺酮及其合成方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4688195A (en) * 1983-01-28 1987-08-18 Texas Instruments Incorporated Natural-language interface generating system
US5083268A (en) * 1986-10-15 1992-01-21 Texas Instruments Incorporated System and method for parsing natural language by unifying lexical features of words
US4935514A (en) * 1989-06-06 1990-06-19 Ethyl Corporation Thiation process
KR0167346B1 (ko) * 1989-06-09 1999-01-15 로버트 에이. 아미테이지 중추신경계 활성을 갖는 헤테로사이클릭 아민
US5273975A (en) * 1989-06-09 1993-12-28 The Upjohn Company Heterocyclic amines having central nervous system activity
US5237975A (en) * 1992-10-27 1993-08-24 Ford Motor Company Returnless fuel delivery system
KR100335548B1 (ko) * 1993-07-27 2002-10-04 파마시아 앤드 업존 캄파니 중추신경계활성을갖는헤테로사이클아민
US6455564B1 (en) * 1999-01-06 2002-09-24 Pharmacia & Upjohn Company Method of treating sexual disturbances
BR0110210A (pt) * 2000-04-21 2003-01-28 Upjohn Co Compostos para o tratamento de fibromialgia e sìndrome de fadiga crÈnica

Also Published As

Publication number Publication date
BR0110323A (pt) 2003-01-07
CN1420886A (zh) 2003-05-28
AU2001255225A1 (en) 2001-11-12
WO2001083483A1 (en) 2001-11-08
PE20011181A1 (es) 2001-11-15
KR20020093090A (ko) 2002-12-12
JP2003531907A (ja) 2003-10-28
CA2404936A1 (en) 2001-11-08
US20020137763A1 (en) 2002-09-26
US20040029909A1 (en) 2004-02-12
US20040266812A1 (en) 2004-12-30

Similar Documents

Publication Publication Date Title
DE69830503D1 (de) Tablette mit verlängerter wirkstoffabgabe zur behandlung der parkinsonkrankheit
EA200400007A1 (ru) ФАРМАЦЕВТИЧЕСКИЙ СОСТАВ ДЛЯ ЭФФЕКТИВНОГО ВВЕДЕНИЯ АПОМОРФИНА, 6aR-(-)-N-ПРОПИЛ-НОРАПОМОРФИНА, ИХ ПРОИЗВОДНЫХ И ИХ ПРОЛЕКАРСТВ
PA8597301A1 (es) Derivados de imidazol-4-il-etinil-piridina
ES2092890T3 (es) Aplicacion del riluzol en el tratamiento de la enfermedad de parkinson y de los sindromes de parkinson.
MY140398A (en) 4-AMINO-6-PHENYL-PYRROLO[2,3-d]PYRIMIDINE DERIVATIVES
AR022860A1 (es) Derivados de camptotecina que poseen actividad antitumoral
EA200601160A1 (ru) 2,6-бисгетероарил-4-аминопиримидины в качестве антагонистов аденозиновых рецепторов
GEP20074208B (en) Substituted amides active at the cannabinoid-1 receptor
BR0305628A (pt) Composição farmacêutica para tratar disfunção sexual num mamìfero compreendendo peptìdeo e seu uso
CY1106258T1 (el) Παραγωγα [6,7-διϋδρο-5h-ιμιδαζο[1,2-α]ιμιδαζολο-3-σουλφονυλαμινο]-προπιοναμιδιου και χρησις των ως αναστολεις κατα την αλληλεπιδρασιν cams και leukointegrins
HN1999000146A (es) Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.
CL2004001050A1 (es) Compuesto derivado de 3'-[4-oxo-3-{[(ciclopropil o 2,2,2-trifluoroetil)amino]carbonil}-1,8-naftiridin-1(4h)-il]-3-sustituido-1-1'-bifenil-4-il; composicion farmaceutica; y uso en el tratamiento o prevencion de asma, bronquitis cronica, enfermedad pul
EE200200471A (et) Farmatseutiline kompositsioon, mis sisaldab kamptotetsiini või selle derivaati kombinatsioonis pürimidiini derivaadiga ning on ette nähtud vähktõve raviks
HUP0401805A2 (hu) Pulmonális betegségek kezelésére szolgáló vegyületek
AR033520A1 (es) (5r)-(metilamino) -5,6-dihidro-4h-imidazo[4,5,1-ij] quinolin-2(1h)-tiona
ES2185153T3 (es) Uso de mefloquina(+) para el tratamiento de la malaria.
NO20062883L (no) Fosfodiesterase-V-inhibitorpreparater
AR023781A1 (es) Formulaciones farmaceuticas
CA2417081A1 (en) New n, n'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors
PA8519501A1 (es) Farnesil transferasa inhibidora del enantiomero de quinolina 1,2-anillado
HRPK20040328B3 (en) Pharmaceutical composition comprising gamma-butyrobetaine
DE602005014087D1 (de) 7h-pyrrolopyrimidinderivate
EA200400877A1 (ru) 2'-гало-3',5'-диалкоксифен-1'-илимино-2-имидазолидиновые производные и их применение для лечения недержания мочи
AR048339A1 (es) Monoclorhidrato de 8- hidroxi-5-((1r)) -1- hidroxi-2- (((1r)-2 ( 4-metoxifenil) -1- metiletil) amino ) eti l) -2 (1h) - quinolinona en form acristalina y el proceso para su preparacion
ES2176642T3 (es) Utilizacion de la sulbutiamina para la obtencion de composiciones farmaceuticas utiles en el tratamiento de ciertos t rastornos psicomotores y psicointelectuales.

Legal Events

Date Code Title Description
FB Suspension of granting procedure